- Tuesday, 16 June 2015
- AstraZeneca appoints Pam Cheng as Executive Vice President, Operations and IT AstraZeneca today announced that Pam P. Cheng has joined the Company as Executive Vice President, Operations and IT. Pam will succeed David Smith, who is retiring after nearly ten years with AstraZeneca.
- Thursday, 11 June 2015
- AstraZeneca reveals findings of archaeological dig as build gets underway at Cambridge Biomedical Campus AstraZeneca today announced the findings of archaeological excavations on the Cambridge Biomedical Campus, which will be home to the Company’s new, purpose-built global R&D centre and corporate headquarters from the end of 2016.
- Monday, 8 June 2015
- New real-world data analysis finds no evidence of increased risk of hospitalisation for heart failure with saxagliptin compared with sitagliptin AstraZeneca today announced results from an observational, retrospective study which found no evidence of increased risk of hospitalisation for heart failure (hHF) with saxagliptin, compared with sitagliptin, both of which are dipeptidyl peptidase-4 (DPP-4) inhibitors, in patients with type 2 diabetes. A similar finding was obtained when comparing the overall DPP-4 class to sulfonylureas. The analysis included patients with and without prior cardiovascular disease (CVD), and among those patients without prior cardiovascular disease (CVD), DPP-4 treatment was associated with statistically significant lower risk for hHF compared to treatment with sulfonylureas.
- Saturday, 6 June 2015
- AstraZeneca presents new positive phase III data on triple therapy approach with dapagliflozin, saxagliptin and metformin for the treatment of type 2 diabetes AstraZeneca today announced positive results from a Phase III study comparing the efficacy and safety of dapagliflozin versus placebo as an add-on to saxagliptin and metformin immediate release (IR) in adults with type 2 diabetes who had inadequate glycaemic control (baseline HbA1c 7% - 10.5%).1 The study met its primary endpoint, with patients receiving the investigational triple combination of dapagliflozin 10 mg, saxagliptin 5 mg and metformin achieving significantly greater mean reductions in HbA1c compared to those treated with placebo, saxagliptin 5 mg and metformin at 24 weeks (–0.82% vs. -0.10%, respectively; p-value<0.0001).1 The results were presented today as an oral presentation (#105-OR) at the 75th Scientific Sessions of the American Diabetes Association (ADA) in Boston.
- Wednesday, 3 June 2015
- AstraZeneca to present data demonstrating progress of its comprehensive diabetes portfolio at the American Diabetes Association 75th Scientific Sessions AstraZeneca today announced that 86 abstracts reporting results of the company’s research and development in diabetes have been accepted for presentation at the 75th Scientific Sessions of the American Diabetes Association (ADA) in Boston, 5-9 June 2015.
- Tuesday, 2 June 2015
- AstraZeneca updates on immuno-oncology combinations development programme at ASCO 2015 AstraZeneca and MedImmune, the Company’s global biologics research and development arm, provided an update on the progress of their combination-focused immuno-oncology pipeline at an investor science event at the American Society of Clinical Oncology (ASCO) meeting in Chicago on 1 June 2015.
- Saturday, 30 May 2015
- AstraZeneca and MedImmune present positive immuno-oncology combination data at ASCO 2015 AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.
- Friday, 29 May 2015
- AstraZeneca and Lilly to collaborate on Immuno-oncology combination clinical trial in solid tumours AstraZeneca and Lilly to collaborate on Immuno-oncology combination clinical trial in solid tumours
- Friday, 22 May 2015
- AstraZeneca provides update on brodalumab development programme Amgen today announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab, an investigational IL-17 receptor inhibitor in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. The announcement follows Amgen’s decision to concentrate on other portfolio priorities after observing suicidal ideation and behaviour events in the brodalumab programme which may result in restrictive labelling.
- Monday, 18 May 2015
- AstraZeneca to invest in new biologics manufacturing facility in Södertälje, Sweden, to support accelerating biologics portfolio AstraZeneca today announced that it plans to invest approximately $285 million in a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden. The new plant will be focused on filling and packaging of protein therapeutics. It is anticipated that the new facility will supply medicines for clinical trial programmes of AstraZeneca and MedImmune, the company’s global biologics research and development arm, from the end of 2018, and will deliver finished products for commercial use once fully operational by 2019.
- 2 Jul
"In research terms, the NHS has real potential to differentiate the UK from other countries and make patient health outcomes even better"2 Jul
"We have over 200 research collaborations in the UK. It's a great place to do science", Mene Pangalos speaking at today's #rcukrig2 Jul